-
Anta Gkelou, principal in the capital strategy team, is promoted to partner, strengthening the firm's commitment to talent development and capital investment expertise
-
Guillaume Baxter, Principal, Industrial Biotechnology Strategy, promoted to Partner, highlighting the firm’s commitment to driving sustainable impact
Paris, April 22, 2024–(BUSINESS WIRE)–Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm headquartered in Paris, London and Milan, is pleased to announce the appointment of two talented team members. Announcement of promotion to partner. He has been with the firm for a long time and has expertise across a variety of strategies. These promotions highlight Sofinova's focus on developing talent within the company and driving impactful change in this sector.
Antoine Papiernik, Managing Partner of Sofinnova Partners, said: “We are pleased to announce the well-deserved promotion of Anta Gkelou and Guillaume Baxter to partner level in recognition of their outstanding growth and expertise since joining us in 2017.” It embodies our commitment to developing and investing in the future.”
Mr. Gkelou joined Sofinova in 2017 as a capital strategy analyst after working as an immunology scientist at Danone Nutricia. She completed her PhD at Imperial College London, conducted research in respiratory diseases at the National Heart and Lung Institute, and did post-doctoral research on heart failure after myocardial infarction at her INSERM in France. I went. Her keen interest in scientific discoveries and their development processes into new products, along with her ability to identify promising investment opportunities, contributed significantly to the company's success. As a capital strategy partner, Gkelou will play a key role in investing in the next generation of early-stage biotechnology companies.
“In my new role as a partner, I look forward to helping build a company that develops products that have a transformative impact on patients' lives,” said Gkelou. “I am committed to the company’s continued success and the challenge of making a meaningful long-term impact.”
Baxter was one of the pioneering members of Sofinova's industrial biotechnology strategy team. He joined the firm in 2017 as a senior associate and has consistently demonstrated a strong passion for industrial biotechnology and impact investing. Baxter has held various positions at Solvay, including Solvay Ventures, and brings solid experience and valuable insight from the chemical industry, further deepening his understanding of the intersection of industry and investment practices. As a partner, Mr. Baxter will continue to use his passion to identify and support breakthrough companies in industrial biotechnology and renewable chemistry, driving positive change across industries worldwide. .
“It has been an honor to have been part of the industrial biotechnology team since its early days,” said Baxter. “As a Partner, I will continue to use my experience to support innovative companies in these sectors, while focusing on establishing Sofinova as a leading sustainable investor driving impactful change. I will do it.”
These promotions reinforce Sofinnova Partners' commitment to talent development and capital investment expertise and further strengthen Sofinnova Partners' position as a leading venture capital firm in the life sciences sector. We remain focused on identifying and supporting innovative companies with the potential to transform healthcare, improve patient outcomes and advance sustainable solutions.
About Sofinova Partners
Sofinnova Partners is Europe's leading venture capital firm in the life sciences sector, specializing in healthcare and sustainability. Based in Paris, London and Milan, the company brings together a team of experts from around the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder spanning the entire life science investment value chain from seed to late stage. We actively partner with ambitious entrepreneurs as lead or cornerstone investors to develop breakthrough innovations that have the potential to positively impact our collective future.
Founded in 1972, Sofinnova Partners is a deeply established European venture capital firm with over 50 years of experience supporting over 500 companies and creating market leaders around the world. Currently, Sofinnova Partners manages his assets of over 2.5 billion euros. For more information, please visit sofinnovapartners.com.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240422219891/ja/
contact address
Bomi Lee
Head of Communications
Sofinova Partners
blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11
North America
Rooney Partners LLC
Kate Barretta
kbarrette@rooneypartners.com
+1 212 223 0561
France
Strategy image
Anne Lane
anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05
England
Optimal strategic communication
Hana Malik
sofinnova@optimumcomms.com
+44 (0) 20 3882 2119
